Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect and Safety of Semaglutide 2.4 mg Once-weekly as Adjunct to Intensive Behavioural Therapy in Subjects With Overweight or Obesity

NCT03611582 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT03611582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03611582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect and Safety of Semaglutide 2.4 mg Once-weekly as Adjunct to Intensive Behavioural Therapy in Subjects With Overweight or Obesity
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
August 1, 2018
Completion date
April 28, 2020
Enrollment
611 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight